124 filings
Page 5 of 7
8-K
cs3jnusy4nr ees31
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
0ad9o7p
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm
8-K
w82sbpc
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
DEFA14A
rd0wt
22 Apr 21
Additional proxy soliciting materials
12:37pm
DEF 14A
3jsnmhzme9027
22 Apr 21
Definitive proxy
12:35pm
10-K
9ouc 699x
25 Mar 21
Annual report
12:00am
8-K
vk01j4p
25 Mar 21
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
12:00am
8-K
osl9p r0z9w1e
19 Jan 21
Entry into a Material Definitive Agreement
10:46am
S-8
3hlmcis
15 Jan 21
Registration of securities for employees
2:01pm
8-K
oj52i
13 Jan 21
Departure of Directors or Certain Officers
12:58pm
8-K
7x8b1 17axabii36to
12 Nov 20
Nkarta Reports Third Quarter 2020 Financial Results
4:08pm
8-K
sdglf78zsarjn28
5 Oct 20
Nkarta Announces Leadership Changes
4:15pm
10-Q
b5f4 7oy89amm7opbx9a
20 Aug 20
Quarterly report
4:51pm
8-K
h2gd479yubss3nguak5z
20 Aug 20
Nkarta Reports Second Quarter 2020 Financial Results
4:12pm
S-8
daf js2c1cxz1z3h
3 Aug 20
Registration of securities for employees
5:16pm
8-K
0xhybnh
14 Jul 20
Amendments to Articles of Incorporation or Bylaws
4:10pm
424B4
hiffwvh63
10 Jul 20
Prospectus supplement with pricing info
9:35pm
S-1MEF
o6u4gg
10 Jul 20
Registration of additional securities for an S-1
6:12am
EFFECT
k5tywp2r
10 Jul 20
Notice of effectiveness
12:16am